- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01108523
Evaluation of Effects of HP828-101 for Moisture Associated Skin Damage
October 9, 2013 updated by: Healthpoint
Open Label Evaluation of the Effects of HP828-101 in the Management of Moisture Associated Skin Damage in Adults
This study evaluates HP828 in the management of moisture associated skin damage after 15 days of use.
Study Overview
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75228
- Golden Acres
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- - The informed consent document must be read, signed, and dated by the subject or the subject's legally authorized representative before conducting any study procedures or exams. In addition, the informed consent document must be signed and dated by the individual who consents the subject before conducting Visit 1. A photocopy of the signed informed consent document must be provided to the subject or subject representative, and the original signed document placed in the subject's chart. If the subject is unable to read or sign the informed consent, or unable to comprehend the information provided in the consent process, a legal guardian, decision making proxy, or next of kin must provide written consent, and if possible, subject must verbally assent to receiving an experimental treatment for their wound.
- Are 18 years of age or older, of either sex and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
- Are expected to remain in the Nursing Home or long-term acute-care (LTAC) for the duration of the study (15 days).
Have moisture associated skin damage including denuded skin or ulceration, where:
- the damage has been present for at least 2 days but less than 6 weeks
- the area of denudation (target wound) measures greater than or equal to 2 and less than or equal to 64 cm2 in total area
- the area of total damage may be greater than 64 cm2
- Are able to verbally respond to the Pre- and Post- Treatment Survey.
- Women of child-bearing potential may participate in the study if they have a negative urine pregnancy test and use adequate birth control, as determined by the Investigator.
- Are capable of maintaining adequate nutritional intake during the study
Exclusion Criteria:
- Have more than 64 cm2 of denuded area.
- Have a full-thickness target wound, or a full-thickness wound within 4 cm of any target wound area.
- Have clinical evidence of bacterial or fungal infection of the target wound area.
- Have, within the area of moisture damaged skin, any tunneling, sinus tracks, shear injury, arterial occlusive disease, or bony prominence or joint with the exception that target wounds may be over dorsal spinous processes, coccyx, ischial tuberosities, or sacroiliac joints.
- Are moribund, or have a severe burn, debilitating immunodeficiency disorder, significant hematologic disorder, metastatic malignancy, uncontrolled diabetes mellitus, or any medical conditions that, in the opinion of the Investigator, places the subject at risk for the study or incapable of healing.
- Are known to have acrodermatitis enteropathica (zinc deficiency).
- Are being treated currently with systemic steroids, immunosuppressive agents, radiation, or chemotherapy.
- Have been treated with enzymatic debridement to the target wound area within 2 days prior to enrollment.
- Have a known sensitivity to ingredients of HP828-101.
- Are using or have used another investigational agent (not including devices such as hearing aids, pace makers, etc.) within 30 days prior to Visit 1.
- The Medical Monitor may declare any subject ineligible for a valid medical reason.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HP828-101
HP828-101 Experimental Formulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 15.
Time Frame: 15 Days
|
15 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rating Scores of Skin Erythema, Skin Pallor, Skin Maceration, Skin Denudation at Day 4, 8, and 12. Proportion of Subjects With no Denuded Skin Area at Day 4, 8, 12, and 15. Pre- and Post-Treatment Surveys
Time Frame: 4, 8, 12, and 15 days
|
4, 8, 12, and 15 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Neeta Nayak, MD, Golden Acres
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Primary Completion (Actual)
July 1, 2010
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
April 20, 2010
First Submitted That Met QC Criteria
April 21, 2010
First Posted (Estimate)
April 22, 2010
Study Record Updates
Last Update Posted (Estimate)
December 6, 2013
Last Update Submitted That Met QC Criteria
October 9, 2013
Last Verified
October 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 828-101-09-017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Abnormalities
-
Enspectra HealthNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSkin Diseases | Skin Abnormalities | Skin Cancer | Skin Lesion | Skin ConditionUnited States
-
Enspectra HealthNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSkin Diseases | Skin Abnormalities | Skin Cancer | Skin Lesion | Skin ConditionUnited States
-
Hillel Yaffe Medical CenterUnknown
-
Avita MedicalBiomedical Advanced Research and Development AuthorityTerminatedSkin; DeformityUnited States
-
Coloplast A/SRecruiting
-
Integrative Skin Science and ResearchArbonneCompleted
-
University of MiamiCompletedAging | Skin AbnormalitiesUnited States
-
University Hospital, AngersNot yet recruitingBody Representation | Feelings | Congenital Skin DisorderFrance
-
Let's DiscoCitruslabsCompletedSkin Abnormalities | AcneUnited States
Clinical Trials on HP828-101
-
HealthpointCompleted
-
HealthpointCompleted
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
HealthpointWithdrawn
-
TR TherapeuticsCompleted
-
Alaunos TherapeuticsCompleted
-
Alaunos TherapeuticsCompletedLymphoma | Multiple Myeloma | Acute Leukemia | Chronic Myeloproliferative Disease | Chronic Lymphoproliferative Disease | Poor-risk Myelodysplasia (MDS)United States
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Flame BiosciencesCompletedHealthy SubjectsUnited States